カテゴリー： LP Information, 世界, 医療/バイオ

世界のMRD（最小残存病変）検査市場予測 2023年-2029年

◆英語タイトル：Global MRD (Minimal Residual Disease) Testing Market Growth 2023-2029
	◆商品コード：LP23JU3681 ◆発行会社（リサーチ会社）：LP Information ◆発行日：2023年5月 ◆ページ数：117 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など ◆産業分野：医療装置＆消耗品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥556,320	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥834,480	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,112,640	見積依頼/購入/質問フォーム

★LP Informationに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界のMRD（最小残存病変）検査市場」は、過去の販売実績から2022年の世界のMRD（最小残存病変）検査の総販売量を検討し、2023年から2029年の予測されるMRD（最小残存病変）検査の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別のMRD（最小残存病変）検査の市場規模を掲載し、XXX百万米ドル規模の世界のMRD（最小残存病変）検査市場の詳細な分析を提供します。本インサイトレポートは、世界のMRD（最小残存病変）検査業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界のMRD（最小残存病変）検査市場における各社の独自のポジションをより深く理解するために、MRD（最小残存病変）検査製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界のMRD（最小残存病変）検査市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。MRD（最小残存病変）検査の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。MRD（最小残存病変）検査の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。MRD（最小残存病変）検査のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

MRD（最小残存病変）検査の世界主要メーカーとしては、ICON plc、 ArcherDX(Invitae)、 ARUP Laboratories、 Asuragen、 Cergentis B.V.、 Bio-Rad Laboratories、 Mission Bio、 Guardant Health、 Invivoscribe、 LabCorp、 Inivata、 Natera、 NeoGenomics Laboratories、 Opko Health、 Quest Diagnostics、 Sysmex Corporation、 Adaptive Biotechnologiesなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別のMRD（最小残存病変）検査市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査ではMRD（最小残存病変）検査市場をセグメンテーションし、種類別 (フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）)、用途別 (専門クリニック・病院、診断研究所、研究機関)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）

・用途別区分：専門クリニック・病院、診断研究所、研究機関

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界のMRD（最小残存病変）検査市場の10年間の市場状況・展望は？
・世界および地域別に見たMRD（最小残存病変）検査市場成長の要因は何か？
・MRD（最小残存病変）検査の市場機会はエンドマーケットの規模によってどのように変化するのか？
・MRD（最小残存病変）検査のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：MRD（最小残存病変）検査の年間販売量2018-2029、地域別現状・将来分析
・MRD（最小残存病変）検査の種類別セグメント：フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）
・MRD（最小残存病変）検査の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・MRD（最小残存病変）検査の用途別セグメント：専門クリニック・病院、診断研究所、研究機関
・MRD（最小残存病変）検査の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界のMRD（最小残存病変）検査市場
・企業別のグローバルMRD（最小残存病変）検査市場データ：2018-2023年の年間販売量、市場シェア
・企業別のMRD（最小残存病変）検査の年間売上：2018-2023年の売上、市場シェア
・企業別のMRD（最小残存病変）検査販売価格
・主要企業のMRD（最小残存病変）検査生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

MRD（最小残存病変）検査の地域別レビュー
・地域別のMRD（最小残存病変）検査市場規模2018-2023：年間販売量、売上
・主要国別のMRD（最小残存病変）検査市場規模2018-2023：年間販売量、売上
・南北アメリカのMRD（最小残存病変）検査販売の成長
・アジア太平洋のMRD（最小残存病変）検査販売の成長
・ヨーロッパのMRD（最小残存病変）検査販売の成長
・中東・アフリカのMRD（最小残存病変）検査販売の成長

南北アメリカ市場
・南北アメリカの国別のMRD（最小残存病変）検査販売量、売上（2018-2023）
・南北アメリカのMRD（最小残存病変）検査の種類別販売量
・南北アメリカのMRD（最小残存病変）検査の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別のMRD（最小残存病変）検査販売量、売上（2018-2023）
・アジア太平洋のMRD（最小残存病変）検査の種類別販売量
・アジア太平洋のMRD（最小残存病変）検査の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のMRD（最小残存病変）検査販売量、売上（2018-2023）
・ヨーロッパのMRD（最小残存病変）検査の種類別販売量
・ヨーロッパのMRD（最小残存病変）検査の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のMRD（最小残存病変）検査販売量、売上（2018-2023）
・中東・アフリカのMRD（最小残存病変）検査の種類別販売量
・中東・アフリカのMRD（最小残存病変）検査の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・MRD（最小残存病変）検査の製造コスト構造分析
・MRD（最小残存病変）検査の製造プロセス分析
・MRD（最小残存病変）検査の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・MRD（最小残存病変）検査の主要なグローバル販売業者
・MRD（最小残存病変）検査の主要なグローバル顧客

地域別のMRD（最小残存病変）検査市場予測レビュー
・地域別のMRD（最小残存病変）検査市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・MRD（最小残存病変）検査の種類別市場規模予測
・MRD（最小残存病変）検査の用途別市場規模予測

主要企業分析
ICON plc、 ArcherDX(Invitae)、 ARUP Laboratories、 Asuragen、 Cergentis B.V.、 Bio-Rad Laboratories、 Mission Bio、 Guardant Health、 Invivoscribe、 LabCorp、 Inivata、 Natera、 NeoGenomics Laboratories、 Opko Health、 Quest Diagnostics、 Sysmex Corporation、 Adaptive Biotechnologies
・企業情報
・MRD（最小残存病変）検査製品
・MRD（最小残存病変）検査販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. The number of remaining cells may be so small that they do not cause any physical signs or symptoms and often cannot even be detected through traditional methods, such as viewing cells under a microscope and/or by tracking abnormal serum proteins in the blood. An MRD positive test result means that residual (remaining) disease was detected. A negative result means that residual disease was not detected,The most widely used tests to measure MRD are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS).
LPI (LP Information)’ newest research report, the “MRD (Minimal Residual Disease) Testing Industry Forecast” looks at past sales and reviews total world MRD (Minimal Residual Disease) Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected MRD (Minimal Residual Disease) Testing sales for 2023 through 2029. With MRD (Minimal Residual Disease) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world MRD (Minimal Residual Disease) Testing industry.
This Insight Report provides a comprehensive analysis of the global MRD (Minimal Residual Disease) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on MRD (Minimal Residual Disease) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global MRD (Minimal Residual Disease) Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for MRD (Minimal Residual Disease) Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global MRD (Minimal Residual Disease) Testing.
The global MRD (Minimal Residual Disease) Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for MRD (Minimal Residual Disease) Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for MRD (Minimal Residual Disease) Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for MRD (Minimal Residual Disease) Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key MRD (Minimal Residual Disease) Testing players cover ICON plc, ArcherDX(Invitae), ARUP Laboratories, Asuragen, Cergentis B.V., Bio-Rad Laboratories, Mission Bio, Guardant Health and Invivoscribe, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of MRD (Minimal Residual Disease) Testing market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Segmentation by application
Specialty Clinics and Hospitals
Diagnostic Laboratories
Research Institutions
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
ICON plc
ArcherDX(Invitae)
ARUP Laboratories
Asuragen
Cergentis B.V.
Bio-Rad Laboratories
Mission Bio
Guardant Health
Invivoscribe
LabCorp
Inivata
Natera
NeoGenomics Laboratories
Opko Health
Quest Diagnostics
Sysmex Corporation
Adaptive Biotechnologies
Key Questions Addressed in this Report
What is the 10-year outlook for the global MRD (Minimal Residual Disease) Testing market?
What factors are driving MRD (Minimal Residual Disease) Testing market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do MRD (Minimal Residual Disease) Testing market opportunities vary by end market size?
How does MRD (Minimal Residual Disease) Testing break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global MRD (Minimal Residual Disease) Testing Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for MRD (Minimal Residual Disease) Testing by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for MRD (Minimal Residual Disease) Testing by Country/Region, 2018, 2022 & 2029
2.2 MRD (Minimal Residual Disease) Testing Segment by Type
2.2.1 Flow Cytometry
2.2.2 Polymerase Chain Reaction (PCR)
2.2.3 Next-Generation Sequencing (NGS)
2.3 MRD (Minimal Residual Disease) Testing Sales by Type
2.3.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2018-2023)
2.3.2 Global MRD (Minimal Residual Disease) Testing Revenue and Market Share by Type (2018-2023)
2.3.3 Global MRD (Minimal Residual Disease) Testing Sale Price by Type (2018-2023)
2.4 MRD (Minimal Residual Disease) Testing Segment by Application
2.4.1 Specialty Clinics and Hospitals
2.4.2 Diagnostic Laboratories
2.4.3 Research Institutions
2.5 MRD (Minimal Residual Disease) Testing Sales by Application
2.5.1 Global MRD (Minimal Residual Disease) Testing Sale Market Share by Application (2018-2023)
2.5.2 Global MRD (Minimal Residual Disease) Testing Revenue and Market Share by Application (2018-2023)
2.5.3 Global MRD (Minimal Residual Disease) Testing Sale Price by Application (2018-2023)
3 Global MRD (Minimal Residual Disease) Testing by Company
3.1 Global MRD (Minimal Residual Disease) Testing Breakdown Data by Company
3.1.1 Global MRD (Minimal Residual Disease) Testing Annual Sales by Company (2018-2023)
3.1.2 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Company (2018-2023)
3.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue by Company (2018-2023)
3.2.1 Global MRD (Minimal Residual Disease) Testing Revenue by Company (2018-2023)
3.2.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Company (2018-2023)
3.3 Global MRD (Minimal Residual Disease) Testing Sale Price by Company
3.4 Key Manufacturers MRD (Minimal Residual Disease) Testing Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers MRD (Minimal Residual Disease) Testing Product Location Distribution
3.4.2 Players MRD (Minimal Residual Disease) Testing Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for MRD (Minimal Residual Disease) Testing by Geographic Region
4.1 World Historic MRD (Minimal Residual Disease) Testing Market Size by Geographic Region (2018-2023)
4.1.1 Global MRD (Minimal Residual Disease) Testing Annual Sales by Geographic Region (2018-2023)
4.1.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic MRD (Minimal Residual Disease) Testing Market Size by Country/Region (2018-2023)
4.2.1 Global MRD (Minimal Residual Disease) Testing Annual Sales by Country/Region (2018-2023)
4.2.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue by Country/Region (2018-2023)
4.3 Americas MRD (Minimal Residual Disease) Testing Sales Growth
4.4 APAC MRD (Minimal Residual Disease) Testing Sales Growth
4.5 Europe MRD (Minimal Residual Disease) Testing Sales Growth
4.6 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales Growth
5 Americas
5.1 Americas MRD (Minimal Residual Disease) Testing Sales by Country
5.1.1 Americas MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023)
5.1.2 Americas MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023)
5.2 Americas MRD (Minimal Residual Disease) Testing Sales by Type
5.3 Americas MRD (Minimal Residual Disease) Testing Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC MRD (Minimal Residual Disease) Testing Sales by Region
6.1.1 APAC MRD (Minimal Residual Disease) Testing Sales by Region (2018-2023)
6.1.2 APAC MRD (Minimal Residual Disease) Testing Revenue by Region (2018-2023)
6.2 APAC MRD (Minimal Residual Disease) Testing Sales by Type
6.3 APAC MRD (Minimal Residual Disease) Testing Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe MRD (Minimal Residual Disease) Testing by Country
7.1.1 Europe MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023)
7.1.2 Europe MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023)
7.2 Europe MRD (Minimal Residual Disease) Testing Sales by Type
7.3 Europe MRD (Minimal Residual Disease) Testing Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa MRD (Minimal Residual Disease) Testing by Country
8.1.1 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023)
8.1.2 Middle East & Africa MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023)
8.2 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Type
8.3 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of MRD (Minimal Residual Disease) Testing
10.3 Manufacturing Process Analysis of MRD (Minimal Residual Disease) Testing
10.4 Industry Chain Structure of MRD (Minimal Residual Disease) Testing
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 MRD (Minimal Residual Disease) Testing Distributors
11.3 MRD (Minimal Residual Disease) Testing Customer
12 World Forecast Review for MRD (Minimal Residual Disease) Testing by Geographic Region
12.1 Global MRD (Minimal Residual Disease) Testing Market Size Forecast by Region
12.1.1 Global MRD (Minimal Residual Disease) Testing Forecast by Region (2024-2029)
12.1.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global MRD (Minimal Residual Disease) Testing Forecast by Type
12.7 Global MRD (Minimal Residual Disease) Testing Forecast by Application
13 Key Players Analysis
13.1 ICON plc
13.1.1 ICON plc Company Information
13.1.2 ICON plc MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.1.3 ICON plc MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 ICON plc Main Business Overview
13.1.5 ICON plc Latest Developments
13.2 ArcherDX(Invitae)
13.2.1 ArcherDX(Invitae) Company Information
13.2.2 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.2.3 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 ArcherDX(Invitae) Main Business Overview
13.2.5 ArcherDX(Invitae) Latest Developments
13.3 ARUP Laboratories
13.3.1 ARUP Laboratories Company Information
13.3.2 ARUP Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.3.3 ARUP Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 ARUP Laboratories Main Business Overview
13.3.5 ARUP Laboratories Latest Developments
13.4 Asuragen
13.4.1 Asuragen Company Information
13.4.2 Asuragen MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.4.3 Asuragen MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Asuragen Main Business Overview
13.4.5 Asuragen Latest Developments
13.5 Cergentis B.V.
13.5.1 Cergentis B.V. Company Information
13.5.2 Cergentis B.V. MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.5.3 Cergentis B.V. MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Cergentis B.V. Main Business Overview
13.5.5 Cergentis B.V. Latest Developments
13.6 Bio-Rad Laboratories
13.6.1 Bio-Rad Laboratories Company Information
13.6.2 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.6.3 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bio-Rad Laboratories Main Business Overview
13.6.5 Bio-Rad Laboratories Latest Developments
13.7 Mission Bio
13.7.1 Mission Bio Company Information
13.7.2 Mission Bio MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.7.3 Mission Bio MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Mission Bio Main Business Overview
13.7.5 Mission Bio Latest Developments
13.8 Guardant Health
13.8.1 Guardant Health Company Information
13.8.2 Guardant Health MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.8.3 Guardant Health MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Guardant Health Main Business Overview
13.8.5 Guardant Health Latest Developments
13.9 Invivoscribe
13.9.1 Invivoscribe Company Information
13.9.2 Invivoscribe MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.9.3 Invivoscribe MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Invivoscribe Main Business Overview
13.9.5 Invivoscribe Latest Developments
13.10 LabCorp
13.10.1 LabCorp Company Information
13.10.2 LabCorp MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.10.3 LabCorp MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 LabCorp Main Business Overview
13.10.5 LabCorp Latest Developments
13.11 Inivata
13.11.1 Inivata Company Information
13.11.2 Inivata MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.11.3 Inivata MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Inivata Main Business Overview
13.11.5 Inivata Latest Developments
13.12 Natera
13.12.1 Natera Company Information
13.12.2 Natera MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.12.3 Natera MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Natera Main Business Overview
13.12.5 Natera Latest Developments
13.13 NeoGenomics Laboratories
13.13.1 NeoGenomics Laboratories Company Information
13.13.2 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.13.3 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 NeoGenomics Laboratories Main Business Overview
13.13.5 NeoGenomics Laboratories Latest Developments
13.14 Opko Health
13.14.1 Opko Health Company Information
13.14.2 Opko Health MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.14.3 Opko Health MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Opko Health Main Business Overview
13.14.5 Opko Health Latest Developments
13.15 Quest Diagnostics
13.15.1 Quest Diagnostics Company Information
13.15.2 Quest Diagnostics MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.15.3 Quest Diagnostics MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Quest Diagnostics Main Business Overview
13.15.5 Quest Diagnostics Latest Developments
13.16 Sysmex Corporation
13.16.1 Sysmex Corporation Company Information
13.16.2 Sysmex Corporation MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.16.3 Sysmex Corporation MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Sysmex Corporation Main Business Overview
13.16.5 Sysmex Corporation Latest Developments
13.17 Adaptive Biotechnologies
13.17.1 Adaptive Biotechnologies Company Information
13.17.2 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.17.3 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Adaptive Biotechnologies Main Business Overview
13.17.5 Adaptive Biotechnologies Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. MRD (Minimal Residual Disease) Testing Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. MRD (Minimal Residual Disease) Testing Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Flow Cytometry
Table 4. Major Players of Polymerase Chain Reaction (PCR)
Table 5. Major Players of Next-Generation Sequencing (NGS)
Table 6. Global MRD (Minimal Residual Disease) Testing Sales by Type (2018-2023) & (Units)
Table 7. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2018-2023)
Table 8. Global MRD (Minimal Residual Disease) Testing Revenue by Type (2018-2023) & ($ million)
Table 9. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Type (2018-2023)
Table 10. Global MRD (Minimal Residual Disease) Testing Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global MRD (Minimal Residual Disease) Testing Sales by Application (2018-2023) & (Units)
Table 12. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2018-2023)
Table 13. Global MRD (Minimal Residual Disease) Testing Revenue by Application (2018-2023)
Table 14. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Application (2018-2023)
Table 15. Global MRD (Minimal Residual Disease) Testing Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global MRD (Minimal Residual Disease) Testing Sales by Company (2018-2023) & (Units)
Table 17. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Company (2018-2023)
Table 18. Global MRD (Minimal Residual Disease) Testing Revenue by Company (2018-2023) ($ Millions)
Table 19. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Company (2018-2023)
Table 20. Global MRD (Minimal Residual Disease) Testing Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers MRD (Minimal Residual Disease) Testing Producing Area Distribution and Sales Area
Table 22. Players MRD (Minimal Residual Disease) Testing Products Offered
Table 23. MRD (Minimal Residual Disease) Testing Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global MRD (Minimal Residual Disease) Testing Sales by Geographic Region (2018-2023) & (Units)
Table 27. Global MRD (Minimal Residual Disease) Testing Sales Market Share Geographic Region (2018-2023)
Table 28. Global MRD (Minimal Residual Disease) Testing Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global MRD (Minimal Residual Disease) Testing Sales by Country/Region (2018-2023) & (Units)
Table 31. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Country/Region (2018-2023)
Table 32. Global MRD (Minimal Residual Disease) Testing Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023) & (Units)
Table 35. Americas MRD (Minimal Residual Disease) Testing Sales Market Share by Country (2018-2023)
Table 36. Americas MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas MRD (Minimal Residual Disease) Testing Revenue Market Share by Country (2018-2023)
Table 38. Americas MRD (Minimal Residual Disease) Testing Sales by Type (2018-2023) & (Units)
Table 39. Americas MRD (Minimal Residual Disease) Testing Sales by Application (2018-2023) & (Units)
Table 40. APAC MRD (Minimal Residual Disease) Testing Sales by Region (2018-2023) & (Units)
Table 41. APAC MRD (Minimal Residual Disease) Testing Sales Market Share by Region (2018-2023)
Table 42. APAC MRD (Minimal Residual Disease) Testing Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC MRD (Minimal Residual Disease) Testing Revenue Market Share by Region (2018-2023)
Table 44. APAC MRD (Minimal Residual Disease) Testing Sales by Type (2018-2023) & (Units)
Table 45. APAC MRD (Minimal Residual Disease) Testing Sales by Application (2018-2023) & (Units)
Table 46. Europe MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023) & (Units)
Table 47. Europe MRD (Minimal Residual Disease) Testing Sales Market Share by Country (2018-2023)
Table 48. Europe MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe MRD (Minimal Residual Disease) Testing Revenue Market Share by Country (2018-2023)
Table 50. Europe MRD (Minimal Residual Disease) Testing Sales by Type (2018-2023) & (Units)
Table 51. Europe MRD (Minimal Residual Disease) Testing Sales by Application (2018-2023) & (Units)
Table 52. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023) & (Units)
Table 53. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa MRD (Minimal Residual Disease) Testing Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Type (2018-2023) & (Units)
Table 57. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Application (2018-2023) & (Units)
Table 58. Key Market Drivers & Growth Opportunities of MRD (Minimal Residual Disease) Testing
Table 59. Key Market Challenges & Risks of MRD (Minimal Residual Disease) Testing
Table 60. Key Industry Trends of MRD (Minimal Residual Disease) Testing
Table 61. MRD (Minimal Residual Disease) Testing Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. MRD (Minimal Residual Disease) Testing Distributors List
Table 64. MRD (Minimal Residual Disease) Testing Customer List
Table 65. Global MRD (Minimal Residual Disease) Testing Sales Forecast by Region (2024-2029) & (Units)
Table 66. Global MRD (Minimal Residual Disease) Testing Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas MRD (Minimal Residual Disease) Testing Sales Forecast by Country (2024-2029) & (Units)
Table 68. Americas MRD (Minimal Residual Disease) Testing Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC MRD (Minimal Residual Disease) Testing Sales Forecast by Region (2024-2029) & (Units)
Table 70. APAC MRD (Minimal Residual Disease) Testing Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe MRD (Minimal Residual Disease) Testing Sales Forecast by Country (2024-2029) & (Units)
Table 72. Europe MRD (Minimal Residual Disease) Testing Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales Forecast by Country (2024-2029) & (Units)
Table 74. Middle East & Africa MRD (Minimal Residual Disease) Testing Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global MRD (Minimal Residual Disease) Testing Sales Forecast by Type (2024-2029) & (Units)
Table 76. Global MRD (Minimal Residual Disease) Testing Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global MRD (Minimal Residual Disease) Testing Sales Forecast by Application (2024-2029) & (Units)
Table 78. Global MRD (Minimal Residual Disease) Testing Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. ICON plc Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 80. ICON plc MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 81. ICON plc MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. ICON plc Main Business
Table 83. ICON plc Latest Developments
Table 84. ArcherDX(Invitae) Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 85. ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 86. ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. ArcherDX(Invitae) Main Business
Table 88. ArcherDX(Invitae) Latest Developments
Table 89. ARUP Laboratories Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 90. ARUP Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 91. ARUP Laboratories MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. ARUP Laboratories Main Business
Table 93. ARUP Laboratories Latest Developments
Table 94. Asuragen Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 95. Asuragen MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 96. Asuragen MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Asuragen Main Business
Table 98. Asuragen Latest Developments
Table 99. Cergentis B.V. Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 100. Cergentis B.V. MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 101. Cergentis B.V. MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Cergentis B.V. Main Business
Table 103. Cergentis B.V. Latest Developments
Table 104. Bio-Rad Laboratories Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 105. Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 106. Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Bio-Rad Laboratories Main Business
Table 108. Bio-Rad Laboratories Latest Developments
Table 109. Mission Bio Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 110. Mission Bio MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 111. Mission Bio MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Mission Bio Main Business
Table 113. Mission Bio Latest Developments
Table 114. Guardant Health Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 115. Guardant Health MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 116. Guardant Health MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Guardant Health Main Business
Table 118. Guardant Health Latest Developments
Table 119. Invivoscribe Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 120. Invivoscribe MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 121. Invivoscribe MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Invivoscribe Main Business
Table 123. Invivoscribe Latest Developments
Table 124. LabCorp Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 125. LabCorp MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 126. LabCorp MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. LabCorp Main Business
Table 128. LabCorp Latest Developments
Table 129. Inivata Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 130. Inivata MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 131. Inivata MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Inivata Main Business
Table 133. Inivata Latest Developments
Table 134. Natera Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 135. Natera MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 136. Natera MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Natera Main Business
Table 138. Natera Latest Developments
Table 139. NeoGenomics Laboratories Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 140. NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 141. NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. NeoGenomics Laboratories Main Business
Table 143. NeoGenomics Laboratories Latest Developments
Table 144. Opko Health Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 145. Opko Health MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 146. Opko Health MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Opko Health Main Business
Table 148. Opko Health Latest Developments
Table 149. Quest Diagnostics Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 150. Quest Diagnostics MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 151. Quest Diagnostics MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Quest Diagnostics Main Business
Table 153. Quest Diagnostics Latest Developments
Table 154. Sysmex Corporation Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 155. Sysmex Corporation MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 156. Sysmex Corporation MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 157. Sysmex Corporation Main Business
Table 158. Sysmex Corporation Latest Developments
Table 159. Adaptive Biotechnologies Basic Information, MRD (Minimal Residual Disease) Testing Manufacturing Base, Sales Area and Its Competitors
Table 160. Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
Table 161. Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 162. Adaptive Biotechnologies Main Business
Table 163. Adaptive Biotechnologies Latest Developments
List of Figures
Figure 1. Picture of MRD (Minimal Residual Disease) Testing
Figure 2. MRD (Minimal Residual Disease) Testing Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global MRD (Minimal Residual Disease) Testing Sales Growth Rate 2018-2029 (Units)
Figure 7. Global MRD (Minimal Residual Disease) Testing Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. MRD (Minimal Residual Disease) Testing Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Flow Cytometry
Figure 10. Product Picture of Polymerase Chain Reaction (PCR)
Figure 11. Product Picture of Next-Generation Sequencing (NGS)
Figure 12. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Type in 2022
Figure 13. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Type (2018-2023)
Figure 14. MRD (Minimal Residual Disease) Testing Consumed in Specialty Clinics and Hospitals
Figure 15. Global MRD (Minimal Residual Disease) Testing Market: Specialty Clinics and Hospitals (2018-2023) & (Units)
Figure 16. MRD (Minimal Residual Disease) Testing Consumed in Diagnostic Laboratories
Figure 17. Global MRD (Minimal Residual Disease) Testing Market: Diagnostic Laboratories (2018-2023) & (Units)
Figure 18. MRD (Minimal Residual Disease) Testing Consumed in Research Institutions
Figure 19. Global MRD (Minimal Residual Disease) Testing Market: Research Institutions (2018-2023) & (Units)
Figure 20. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2022)
Figure 21. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Application in 2022
Figure 22. MRD (Minimal Residual Disease) Testing Sales Market by Company in 2022 (Units)
Figure 23. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Company in 2022
Figure 24. MRD (Minimal Residual Disease) Testing Revenue Market by Company in 2022 ($ Million)
Figure 25. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Company in 2022
Figure 26. Global MRD (Minimal Residual Disease) Testing Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Geographic Region in 2022
Figure 28. Americas MRD (Minimal Residual Disease) Testing Sales 2018-2023 (Units)
Figure 29. Americas MRD (Minimal Residual Disease) Testing Revenue 2018-2023 ($ Millions)
Figure 30. APAC MRD (Minimal Residual Disease) Testing Sales 2018-2023 (Units)
Figure 31. APAC MRD (Minimal Residual Disease) Testing Revenue 2018-2023 ($ Millions)
Figure 32. Europe MRD (Minimal Residual Disease) Testing Sales 2018-2023 (Units)
Figure 33. Europe MRD (Minimal Residual Disease) Testing Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales 2018-2023 (Units)
Figure 35. Middle East & Africa MRD (Minimal Residual Disease) Testing Revenue 2018-2023 ($ Millions)
Figure 36. Americas MRD (Minimal Residual Disease) Testing Sales Market Share by Country in 2022
Figure 37. Americas MRD (Minimal Residual Disease) Testing Revenue Market Share by Country in 2022
Figure 38. Americas MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2018-2023)
Figure 39. Americas MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2018-2023)
Figure 40. United States MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC MRD (Minimal Residual Disease) Testing Sales Market Share by Region in 2022
Figure 45. APAC MRD (Minimal Residual Disease) Testing Revenue Market Share by Regions in 2022
Figure 46. APAC MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2018-2023)
Figure 47. APAC MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2018-2023)
Figure 48. China MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 52. India MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe MRD (Minimal Residual Disease) Testing Sales Market Share by Country in 2022
Figure 56. Europe MRD (Minimal Residual Disease) Testing Revenue Market Share by Country in 2022
Figure 57. Europe MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2018-2023)
Figure 58. Europe MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2018-2023)
Figure 59. Germany MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 60. France MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales Market Share by Country in 2022
Figure 65. Middle East & Africa MRD (Minimal Residual Disease) Testing Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2018-2023)
Figure 68. Egypt MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country MRD (Minimal Residual Disease) Testing Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of MRD (Minimal Residual Disease) Testing in 2022
Figure 74. Manufacturing Process Analysis of MRD (Minimal Residual Disease) Testing
Figure 75. Industry Chain Structure of MRD (Minimal Residual Disease) Testing
Figure 76. Channels of Distribution
Figure 77. Global MRD (Minimal Residual Disease) Testing Sales Market Forecast by Region (2024-2029)
Figure 78. Global MRD (Minimal Residual Disease) Testing Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global MRD (Minimal Residual Disease) Testing Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global MRD (Minimal Residual Disease) Testing Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global MRD (Minimal Residual Disease) Testing Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global MRD (Minimal Residual Disease) Testing Revenue Market Share Forecast by Application (2024-2029)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のMRD（最小残存病変）検査市場予測 2023年-2029年(Global MRD (Minimal Residual Disease) Testing Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界のMRD（最小残存病変）検査市場予測 2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp